The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyiadzis, Michael M, Aksentijevich, Ivan, Arber, Daniel A, Barrett, John, Brentjens, Renier J, Brufsky, Jill, Cortes, Jorge, De Lima, Marcos, Forman, Stephen J, Fuchs, Ephraim J, Fukas, Linda J, Gore, Steven D, Litzow, Mark R, Miller, Jeffrey S, Pagel, John M, Waller, Edmund K, Tallman, Martin S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574947/
https://www.ncbi.nlm.nih.gov/pubmed/33077513
http://dx.doi.org/10.1136/jitc-2020-000810
_version_ 1783597724186181632
author Boyiadzis, Michael M
Aksentijevich, Ivan
Arber, Daniel A
Barrett, John
Brentjens, Renier J
Brufsky, Jill
Cortes, Jorge
De Lima, Marcos
Forman, Stephen J
Fuchs, Ephraim J
Fukas, Linda J
Gore, Steven D
Litzow, Mark R
Miller, Jeffrey S
Pagel, John M
Waller, Edmund K
Tallman, Martin S
author_facet Boyiadzis, Michael M
Aksentijevich, Ivan
Arber, Daniel A
Barrett, John
Brentjens, Renier J
Brufsky, Jill
Cortes, Jorge
De Lima, Marcos
Forman, Stephen J
Fuchs, Ephraim J
Fukas, Linda J
Gore, Steven D
Litzow, Mark R
Miller, Jeffrey S
Pagel, John M
Waller, Edmund K
Tallman, Martin S
author_sort Boyiadzis, Michael M
collection PubMed
description Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.
format Online
Article
Text
id pubmed-7574947
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75749472020-10-21 The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia Boyiadzis, Michael M Aksentijevich, Ivan Arber, Daniel A Barrett, John Brentjens, Renier J Brufsky, Jill Cortes, Jorge De Lima, Marcos Forman, Stephen J Fuchs, Ephraim J Fukas, Linda J Gore, Steven D Litzow, Mark R Miller, Jeffrey S Pagel, John M Waller, Edmund K Tallman, Martin S J Immunother Cancer Position Article and Guidelines Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia. BMJ Publishing Group 2020-10-19 /pmc/articles/PMC7574947/ /pubmed/33077513 http://dx.doi.org/10.1136/jitc-2020-000810 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Position Article and Guidelines
Boyiadzis, Michael M
Aksentijevich, Ivan
Arber, Daniel A
Barrett, John
Brentjens, Renier J
Brufsky, Jill
Cortes, Jorge
De Lima, Marcos
Forman, Stephen J
Fuchs, Ephraim J
Fukas, Linda J
Gore, Steven D
Litzow, Mark R
Miller, Jeffrey S
Pagel, John M
Waller, Edmund K
Tallman, Martin S
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
title The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
title_full The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
title_fullStr The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
title_full_unstemmed The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
title_short The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
title_sort society for immunotherapy of cancer (sitc) clinical practice guideline on immunotherapy for the treatment of acute leukemia
topic Position Article and Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574947/
https://www.ncbi.nlm.nih.gov/pubmed/33077513
http://dx.doi.org/10.1136/jitc-2020-000810
work_keys_str_mv AT boyiadzismichaelm thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT aksentijevichivan thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT arberdaniela thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT barrettjohn thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT brentjensrenierj thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT brufskyjill thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT cortesjorge thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT delimamarcos thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT formanstephenj thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT fuchsephraimj thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT fukaslindaj thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT gorestevend thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT litzowmarkr thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT millerjeffreys thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT pageljohnm thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT walleredmundk thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT tallmanmartins thesocietyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT boyiadzismichaelm societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT aksentijevichivan societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT arberdaniela societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT barrettjohn societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT brentjensrenierj societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT brufskyjill societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT cortesjorge societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT delimamarcos societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT formanstephenj societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT fuchsephraimj societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT fukaslindaj societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT gorestevend societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT litzowmarkr societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT millerjeffreys societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT pageljohnm societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT walleredmundk societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia
AT tallmanmartins societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofacuteleukemia

Ejemplares similares